Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

NCT04138927 is registered in ClinicalTrials.gov with Rigel Pharmaceuticals as lead sponsor.

NCT NCT04138927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04138927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Lead sponsor
Rigel Pharmaceuticals
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
October 30, 2019
Completion date
April 30, 2024
Enrollment
90 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

warm antibody autoimmune hemolytic anemia